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INTRODUCTION  
An estimated 6.6 million people die from cancer each year across the world; about 
two thirds of these patients will experience pain and between 45 and 56% of all 
cancer patients will experience pain of moderate to severe intensity [22]. There is 
broad consensus that opioid-based pharmacotherapy is the first-line strategy for the 
treatment of moderate to severe cancer pain [5,18,16]. Yet despite advances 
associated with the increased availability and development of new opioids, under 
prescribing of analgesia in cancer remains prevalent with approximately one third of 
patients still not receiving pain medication proportional to their pain intensity [10] 
Effective cancer pain management in the community setting is particularly 
challenging, with pain reported to be well controlled for only 18% of those who die at 
home in the UK [24].  
Whilst cancer-related pain remains a major public health problem worldwide [6] the 
problem exists in a context of growing concern about over prescribing of strong 
opioids in other patient groups, particularly in non-cancer chronic pain. The growth in 
strong opioid utilisation across the USA [26] and some European countries [3] has 
prompted fears of an international opioid prescribing epidemic.  
The UK picture is similar; the growing use of buprenorphine, oxycodone 
hydrochloride and morphine sulphate in England increased annual costs for these 
drugs alone by over £10m between 2002 and 2013 [15]. Aggregated dispensing data 
reported by the UK National Health and Social Care Information Centre (NHSCIC) 
shows a 466% increase in opioid prescribing between 2000 and 2010. However, for 
cancer patients, opioid prescribing has not increased to the same extent and still 
represents only 16.1% of all opioid prescriptions issued in the UK [15].   
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In order to improve the management of cancer pain a number of important barriers 
need to be overcome [17] one of which is enabling more appropriate patient access 
to strong opioid treatment. In this study we determine the extent and duration of 
strong opioid prescribing in a cohort of cancer patients before death and the factors 
that influence prescribing to determine the scope for earlier intervention.     
 
METHODS 
Research Question  
What is the extent and duration of strong opioid prescribing for cancer patients 
before death and what are the factors that influence prescribing?  
 
Data and Patients  
We obtained ethical approval to link UK Cancer Registry data with the corresponding 
electronic primary care medical records of adult patients (at least 18 years of age at 
time of death) who died from cancer (verified by death certification) over a seven 
year period (2005 to 2012) in a large UK city (Leeds). Cause of death, demographic 
information including Index of Multiple Deprivation (IMD), date of diagnosis and 
cancer site and stage, treatment history and place of death is most reliably recorded 
by the Cancer Registry. This registry is part of Public Health England and records 
every new cancer diagnosis within the UK and has a long-term role in monitoring 
trends in cancer incidence and survival. The Cancer Registry maximises dataset 
completeness by obtaining data from multiple sources including the Office of 
National Statistics, medical records, histopathology services and death certification.  
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Analgesic prescribing history is most reliably recorded within SystmOne which 
records all prescriptions issued in General Practice (Primary Care) and is the most 
reliable means of charting analgesic prescribing over time. Data on pain intensity is 
not routinely recorded within UK electronic patient care records and so was not 
available for analysis. The linkage of the two data sources was undertaken using an 
Open Pseudonymiser system which creates an encrypted code based on NHS 
number, patient sex and year of birth. We extracted all prescriptions for analgesics 
issued to each patient in the linked cohort during the 12 months prior to death.  (See 
Appendix 1 for list of analgesics).  
Leeds is the third largest city in the UK with a population of 750,000, 85% of which 
are white, 6% Asian, and 3.5 % black. Within Leeds, there are 545 general 
practitioners (family physicians) working in 109 general practices. Our data 
represents community prescribing activity from all General Practices in the city 
during this period (2005-2012). 
Statistical Analysis 
Patients were stratified into one of three analgesic groups: Group 1, no prescription 
group: patients who had received no analgesic prescriptions within the last year of 
life. Group 2, non-opioids / weak opioids: patients who had received at least one 
prescription for either a non-opioid or weak opioid but had not received a prescription 
for a strong opioid within the last year of life. Group 3, strong opioid: patients who 
had received at least one prescription for a strong opioid within the last year of life. 
Demographic characteristics as well as clinical and treatment factors were described 
for all patients stratified by the three analgesic groups. Differences in demographic, 
clinical and treatment factors across the three analgesic groups were derived from 
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univariate multinomial logistic regression models. Data from these models are 
presented as relative risk ratios (RRR) with 95% confidence intervals. Survival since 
diagnosis is described in terms of the number of weeks that elapsed between 
diagnosis and death and was stratified by cancer type. Frequencies (%) of 
prescriptions, number (%) of patients receiving at least one prescription, and median 
(IQR) prescriptions  per patient are presented stratified by analgesic group. Timing of 
prescriptions prior to death is presented as median (IQR) weeks between first 
prescription and death stratified by analgesic group. The final analysis was to 
explore the factors associated with receiving an early or late prescription for a strong 
opioid. The median weeks before death that a first strong opioid was prescribed was 
used as a cut point to dichotomize the sample between those who received an early 
prescription of a strong opioid ZHHNVEHIRUHGHDWKand those who received a 
late prescription for a strong opioid ZHHNVEHIRUHGHDWK. For those individuals 
who received at least one strong opioid prescription a multivariable logistic 
regression analysis was used to model the association between demographic, 
clinical and treatment factors and the risk of receiving an early or late strong opioid 
prescription. Data from this model are presented as odds ratios (OR) with 95% 
confidence intervals. 
 
RESULTS   
Sample characteristics 
The study included 6,080 cancer patients who died between December 2005 and 
February 2012, of whom 4610 (75.8%) had received one or more prescriptions for 
analgesics. Patient characteristics are described in Table 1. Our cohort was 
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representative of all UK cancer patients [4] in relation to cancer prevalence and 
mortality. Of those who had received some form of cancer treatment (93.9%), the 
most common were chemotherapy (42.6%), surgery (38.3%), radiotherapy (35.1%) 
or hormone therapy (14.3%). Ethnicity data was unavailable for 34.7% and limited in 
detail for the remainder, of whom 63.1% were classified as White and 2.2 % other. 
An Index of Multiple Deprivation (IMD) was extracted for all patients. Over half 
(52.5%) had an IMD rank of 1 or 2 indicating a high level of deprivation and a 
PLQRULW\IHOOZLWKLQ,0'UDQNµOHDVWGHSULYHG¶3ODFHRIGHDWKZDVVSOLW
between hospital (32.1%) hospice (31.7%) and home (26.6%). This pattern is 
broadly similar to UK national data on place of death for cancer patients [20] but 
reflects relatively good provision of palliative care services in Leeds. Nationally there 
are slightly more deaths in hospital (37.8%), and at home (29.6%), and fewer deaths 
in hospice (17.8%).  
Median survival from diagnosis for the whole cohort was 60 weeks (IQR 22-147). 
Survival from diagnosis by cancer type was as expected: shortest in patients with 
primary of unknown origin, brain and neurological cancers, and lung cancer, and 
longest for patients with breast or prostate cancer.   
 
Extent of analgesic prescribing  
We found 96,810 analgesic prescriptions were issued to 4,610 patients; 31.5% of all 
prescriptions were for non opioids, 25.2% weak opioids and 43.3% strong opioids. 
Forty eight percent of patients received at least one prescription for a strong opioid. 
Over one third (36.7%) of all strong opioid prescriptions issued were for morphine, 
followed by diamorphine (15.9%) oxycodone (11.2%), fentanyl (10.4%), 
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buprenorphine (3.7%) and other (0.3%) (Figure 1). The median number of 
prescriptions for a strong opioid per patient was 4 (IQR 2-12).  
 
 
Strong opioid prescriptions 
Forty eight percent (95% CI 47-49%) of people who died of cancer received at least 
one prescription of strong opioid in the last year of life. Multivariable logistic 
regression models revealed no differences in the chance of receiving a strong opioid 
with age or sex, however compared to dying in a hospice, individuals dying in the 
hospital were 60% less likely to receive a strong opioid in the community in the last 
year of life ( RRR 0.4, CI 0.3-0.5,P<0.001). Conversely patients who had received 
chemotherapy treatment in the last year of life were 30% more likely to have 
received a strong opioid compared to those who did not have chemotherapy 
treatment (RRR 1.3, CI1.1-1.6, P<1.1-1.6) 
Timing and duration of strong opioid prescriptions  
We examined the timing of strong opioid prescribing by calculating the interval in 
weeks between the first prescription event (by prescription type described in 
Appendix 1) and death. For those patients who had received a strong opioid, the 
median interval between first prescription for any strong opioid and death was 9 
weeks (IQR 3-23). The median interval between first prescription and death for the 
specific opioids morphine, oxycodone or fentanyl was slightly longer than the overall 
median, 11 weeks (IQR 4-24 and 4-29 respectively) (Table 2). Diamorphine was the 
opioid prescribed closest to death with a median interval before death of 1 week 
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(IQR1-3) which is consistent with its typical clinical use in the UK as a subcutaneous 
infusion in the last days of life. Figure 2 shows a rapid increase in strong opioid 
prescriptions issued in the last 3 months of life. However, at 6 weeks before death 
only 30% of cancer patients had been prescribed a strong opioid. 
 
To investigate the factors associated with receiving an early or late first prescription 
for a strong opioid we dichotomized the group based on the timing of each persons¶ 
ILUVWVWURQJRSLRLGSUHVFULSWLRQHDUO\JURXSZHHNVEHIRUHGHDWK late group 
weeks before death. Table 3 summarises a multivariable logistic regression model 
that quantifies the relationship between early or late prescription of strong opioid and 
patient¶V demographic and treatment variables. This model reveals that compared to 
being under 50 years of age, those 60 years and over were between 1.7 (1.2-2.4) 
and 4.3 (1.9-9.7) times more likely to receive a late prescription for a strong opioid. 
Figure 3 shows the decreasing proportion of early first prescriptions for a strong 
opioid with increasing age. 
Compared to patients who died in a hospice, those who died in a hospital were 40% 
more likely to receive a late prescription in the community for a strong opioid (RRR 
1.4, 95% CI 1.1-1.7,P<0.01). Patients who died in their own home or a care home 
were 2.6 and 2.8 times respectively more likely to receive a late prescription for a 
strong opioid. Further analysis on those individuals who died in their own home or a 
care home revealed that although they were just as likely to receive at least one 
strong opioid prior to death as those dying in hospice, they were 7.5 (4.5-12.1) and 
4.1 (1.9-8.6) times more likely to receive diamorphine as their first strong opioid 
prescription which in 75% of cases was prescribed 3 weeks or less prior to death.  
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Patients who had surgery were 40% more likely to receive a late prescription for a 
strong opioid compared to patients who did not have surgery. In contrast, patients 
who received chemotherapy and/or radiotherapy were 30% more likely to have 
received an early prescription for a strong opioid compared to patients who had not 
received these treatments.  
DISCUSSION 
There are very few longitudinal population level studies of opioid prescribing in 
patients dying of cancer. Previous studies chart opioid prescribing over the last 3 
months of life [11,2] sum total opioid dosage over a designated period [13] or report 
dose at specific time points [2]. This study is the first to accurately determine the 
median interval between first prescription of a strong opioid and death in a large 
population by charting analgesic prescribing daily over the last year of life.  
Almost half (48%) of all patients in our study received a strong opioid before death, 
though only 30% had received a strong opioid at 6 weeks before death. These 
figures are consistent with a recent (2012) UK study [11] which reported 43.6% of 
cancer patients receive an opioid in the last three months of life and two studies 
based in the Netherlands [2] and Denmark [12] which report the proportion of cancer 
patients prescribed an opioid in the last 12 months of life to be 51% and 54% 
respectively. In the context of the evidence on pain prevalence in advanced cancer 
(estimated to be between 62 and 86% [22,23] ) our data supports the hypothesis of 
potential under treatment of cancer pain and suggests that many more patients with 
advanced cancer and pain may benefit from a strong opioid analgesic.  
Of those who did receive a strong opioid, the median interval between first 
prescription and death was short (9 weeks). This does not correspond to the 
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evidence on the onset of severe pain in this patient group [22,3,23] which for many 
patients occurs much earlier in the cancer trajectory. We examined whether late 
diagnosis could account for this but median survival for our sample from diagnosis 
was 60 weeks suggesting that most opioid prescribing in fact occurred late in the 
trajectory between diagnosis and death, regardless of cancer duration. Additionally 
over 90% of all patients in the cohort had received some form of cancer treatment 
therefore it was not the absence of a cancer diagnosis or poor engagement with 
cancer services that hindered timely access to an opioid. The association between 
treatment with chemotherapy or radiotherapy and earlier opioid prescription suggests 
that more active oncology management provides opportunities to identify pain. 
Overall, less than half of all patients that die from cancer receive a strong opioid, and 
in those that did, an average of four prescriptions were issued over a median 
duration of 9 weeks before death.  
We found older patients were equally likely to receive an opioid as younger patients, 
though if they did receive an opioid, it was significantly later than in younger patients 
with a clear relationship between increasing age and shorter treatment duration. 
Inequity of access to opioids among older patients has been highlighted in previous 
studies [11,7] although the reasons for this remains unclear.  A meta-analysis of 46 
studies on cancer pain prevalence found no differences between younger and older 
cancer patients in terms of pain severity [22]. Therefore further research is needed to 
explore why later opioid prescribing exists in older cancer patients.  
This is the first study to explore the relationship between opioid prescribing for 
cancer pain in relation to place of death. Patients who died in hospital were 60% less 
likely to receive a strong opioid in the community in the year before death than 
patients who died in a hospice. We considered whether this finding could be 
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attributable to our dataset being derived exclusively from community issued 
prescriptions. However given that for most cancer patients 90% of the last year of life 
is spent at home (the average length of a cancer inpatient stay in the UK is 8 days 
and the average number of admissions in the last year of life is 5) [19] it is highly 
unlikely that missed hospital issued prescriptions would alter this finding. We 
therefore hypothesise that the association between hospital deaths and lower levels 
and later prescribing of a strong opioid might reflect poor pain control as a reason for 
admission. Possible contributory factors to dying in hospital may be poor planning, 
and a lack of coordinated care or specialist palliative care involvement. Although 
patients who died at home or in a care home were equally likely to receive an opioid 
as those who die in a hospice, the first opioid prescription was issued much later and 
in 75% of cases was for diamorphine, a drug typically used in the last days of life.  
We hypothesise that although deaths at home may be associated with lower 
prevalence of complex problems or symptoms that would otherwise trigger hospital 
or hospice admission, the timing and nature of prescribing could indicate under 
treatment within this group. Earlier integration of specialist palliative care may be one 
solution to this; A multi- centre study of 1,450 patients with cancer pain comparing 
oncology care alone to early integration of palliative care alongside oncology care 
found that early access was associated with a 31% reduced risk of suffering from 
severe pain [7]. This may be largely attributable to the enhanced opportunity for pain 
monitoring and screening. The potential impact of improving the opportunities for 
screening for cancer pain on prescribing should not be underestimated. A recent 
study demonstrated a 179% increase in the use of opioids in patients dying of cancer 
after the introduction of a daily pain measurement using a numerical rating scale 
[19].  
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This study has limitations. Firstly, the population is derived from a single UK city, and 
whilst we have been able to determine the population is broadly representative of the 
UK cancer population in terms of prevalence of cancer type, age, sex and survival, 
the extent to which opioid prescribing is representative of national and international 
activity is harder to determine. The prescribing activity is derived from 545 general 
practitioners (family physicians) working within 109 general practices so it represents 
a large number of prescribers. The higher rates of death at home or in hospice in 
Leeds compared to UK national data probably reflect a good provision of community 
palliative care. It is possible that our data may represent an over-estimate of strong 
opioid prescribing practice than in the UK in general. Secondly, we have used cause 
of death data derived from death certification to identify a cohort who have died from 
cancer. Previous cancer mortality studies exploring analgesic prescribing report on 
populations who have died with a diagnosis of cancer rather died of cancer. We 
acknowledge cause of death recording on death certification is imperfect, however 
two recent studies [20,9] suggest the level of inaccuracy is overstated and is in fact 
as low as 4%. We acknowledge a margin of error exists and is likely to be evident in 
our dataset however we are confident it does not undermine our attempt to make 
methodological progress by defining a cohort who have died from, rather than with, 
cancer.  The data used in this study is derived from a live clinical system and as 
such is likely to represent errors or omissions inherent within that system.  We also 
acknowledge that the data on analgesic prescribing is restricted to community issued 
prescriptions and whilst this is the most appropriate source to capture longitudinal 
prescribing data over a 12 month period it cannot capture prescribing during 
inpatient admissions to hospices or acute hospitals (although to some extent 
prescribing that continues following discharge may reflect inpatient activity).  
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Finally, and in common with other retrospective cohort studies of this type [2, 7,11, 
12] we were not able to directly match level of analgesic prescription with the level of 
patient reported pain intensity as the latter data are not routinely recorded in 
electronic patient records. We recognise the lack of pain assessment is a limiting 
factor in assessing the effectiveness of pain management but the purpose of this 
study is to capture prescribing practice in the context of routine care and identify 
factors that are associated with poorer access to strong opioids. 
 
CONCLUSIONS 
We have identified for the first time the relatively late onset and short duration of 
strong opioid treatment in cancer patients prior to death. This pattern of prescribing 
does not match epidemiological data which points to earlier onset of pain that is 
moderate to severe in intensity for half of all patients with cancer. The clinical 
implications of this study are clear; within the advanced cancer population there is a 
need to develop mechanisms to improve pain assessment and initiate a more 
proactive approach to prescribing, particularly for older patients. One mechanism to 
achieve this is through earlier integration of palliative care to improve pain control 
and begin to address the inequalities evidenced here.     
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Figure and Table Legends  
Figure 1 legend: 
Data presented are the proportion of patients receiving at one prescription event for 
each of the strong opioid drugs in the last year of life.  
3URSRUWLRQRIµ$Q\¶VWURQJRSLRLGLVFDOFXODWHGDVWKHQXPEHURISDWLHQWVUHFHLYLQJDW
least one strong opioid divided by the total number of patients in the dataset 
(n=6080).  
** Other strong opioids were: Rapid release fentanyl, Dipipanone, Dipinanone 
Meptazinol, Pethadin 
 
Table 1 legend:  
Data are presented as n(%) except survival which is median (IQR). Proportions are 
FDOFXODWHGDVURZSURSRUWLRQVRIWKHµ$OO¶FROXPQ 
* all p values are derived from chi-VTXDUHGFRPSDULVRQVQRWLQFOXGLQJWKHµ$OO¶
column) except for survival which is derived from Kurskal Wallis equality-of-
populations rank test.1=most deprived, 5=least deprived. 
 
Table 2 legend:  
* Other strong opioids were: Rapid release fentanyl, Dipipanone, Meptazinol, 
Pethidine. 
Data presented here does not include patients with no prescription events (n=1470). 
Data are presented as median (IQR). 
 
Table 3 legend: 
All data are presented as odds ratios (95% CI). The early prescription group were 
the referent category, therefore the model was predicting the odds or receiving a late 
opioid prescription 
*p<0.01, **0<0.001 
 
19 
 
Table 1 Patient Characteristics 
  Prescription Level  
Variable All 
n=6080 
1RSUHV¶ 
n=1470 
(24.2) 
Non-opioid / weak 
opioid 
n=1691 (27.8) 
Strong 
Opioid 
n=2919 
(48.0) 
P* 
Age at diagnosis 
<50 
50-59 
60-69 
70-79 
80-89 
>90 
 
414 (6.8) 
794 (12.6) 
1570 (25.8) 
2000 (32.9) 
1168 (19.2) 
134 (2.2) 
 
111 (26.8) 
174 (21.9) 
358 (22.8) 
500 (25) 
294 (25.2) 
33 (24.6) 
 
73 (17.6) 
172 (21.7) 
392 (25) 
585 (29.3) 
413 (35.4) 
56 (41.8) 
 
230 (55.6) 
448 (56.4) 
820 (52.2) 
915 (45.8) 
461 (39.5) 
45 (33.6) 
 
<0.001 
Sex 
Male 
Female 
 
3253 
2827 
 
783 (24.1) 
689 (24.3) 
 
901 (27.7) 
791 (27.9) 
 
1569 (48.2) 
1350 (47.8) 
 
0.933 
Ethnic description 
White 
Not known 
Other 
 
3836 
2112 
132 
 
954 (24.9) 
476 (22.5) 
40 (30.3) 
 
1075 (28.0) 
593 (28.1) 
23 (17.4) 
 
1807 (47.1) 
1043 (49.4) 
69 (52.7) 
 
0.01 
IMD rank 
1 
2 
3 
4 
5 
 
1945 
1247 
905 
1232 
748 
 
436 (22.4) 
329 (26.4) 
241 (26.6) 
292 (23.7) 
171 (22.8) 
 
519 (32.7) 
334 (26.8) 
275 (30.4) 
350 (28.4) 
213 (28.5) 
 
990 (50.9) 
584 (46.8) 
389 (43.0) 
590 (47.9) 
364 (48.7) 
 
<0.01 
Place of death 
Hospital 
Hospice 
3DWLHQW¶VKRPH 
Care home 
Other 
 
1949 
1930 
1619 
496 
86 
 
508 (26.1) 
395 (20.5) 
415 (25.6) 
123 (24.8) 
29 (33.7) 
 
877 (45.0) 
476 (24.5) 
203 (12.5) 
120 (24.2) 
12 (17.4) 
 
564 (28.9) 
1059 (54.9) 
1001 (61.8) 
253 (51.0) 
42 (48.8) 
 
<0.001 
Cancer site 
Lung 
Upper GI 
Colorectal 
Breast 
Prostate 
Urological  
Gynaecological 
Head & Neck 
Brain & Neurological 
Primary Unknown 
Other 
 
1668 
933 
796 
612 
579 
445 
349 
252 
144 
60 
242 
 
413 (24.8) 
237 (25.4) 
191 (24.0) 
131 (20.4) 
118 (20.4) 
104 (23.4) 
88 (25.2) 
72 (28.6) 
48 (33.3) 
11 (18.3) 
57 (23.6) 
 
400 (24.0) 
239 (25.6) 
224 (28.1) 
200 (32.7) 
182 (31.4) 
158 (35.5) 
100 (28.7) 
61 (24.2) 
46 (31.9) 
14 (23.3) 
67 (27.7) 
 
855 (51.3) 
457 (49.0) 
381 (47.9) 
281 (45.9) 
279 (48.2) 
183 (41.1) 
161 (46.1) 
119 (47.2) 
50 (34.7) 
35 (58.3) 
118 (48.8) 
 
<0.001 
Survival  
Diagnosis to death 
(months) 
 
14 (6-34) 
 
13 (5-31) 
 
12 (4-32) 
 
15 (7-37) 
 
<0.001 
Oncology treatment 
Surgery 
   No 
   Yes 
Radiotherapy 
   No 
   Yes 
Chemotherapy 
   No 
   Yes 
Hormone therapy 
   No 
   Yes 
 
 
3750 
2330 
 
3945 
2315 
 
3487 
2593 
 
5213 
867 
 
 
926 (24.7) 
554 (23.4) 
 
931 (23.6) 
359 (25.3) 
 
876 (25.1) 
594 (22.9) 
 
1296 (24.9) 
174 (20.1) 
 
 
947 (25.3) 
744 (31.9) 
 
1166 (29.6) 
525 (24.6) 
 
1088 (31.2) 
603 (25.3) 
 
1401 (26.9) 
290 (33.5) 
 
 
1877 (50.1) 
1042 (44.7) 
 
1848 (46.8) 
1071 (50.2) 
 
1523 (43.7) 
1396 (48.01) 
 
2516 (48.3) 
403 (46.5)) 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
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Table 2 Median (IQR) weeks elapsed between first prescription event and death. 
Variable Weeks between first 
prescription event and death 
Any prescription type 
 
21 (7-42) 
Prescription type 
Non opioids 
Weak opioids 
Strong opioids 
 
 
38 (19-48) 
29 (13-47) 
9 (3-23) 
 
Strong opioids  
Morphine 
Oxycodone 
Fentanyl 
Burpenorphine 
Diamorphone 
Other* 
 
11 (4-24) 
11 (4-29) 
12 (4-23) 
16 (5-32) 
1 (1-3) 
24 (9-44) 
  
  
  
Table 3 
 
Variable Predicting late strong opioid prescription 
Age at diagnosis 
<50 
50-59 
60-69 
70-79 
80-89 
>90 
 
- 
1.4 (0.9-2) 
1.7 (1.2)** 
2.1 (1.5-2.9)** 
2.7 (1.9-4)** 
4.3 (1.9-9.7)** 
Sex 
Male 
Female 
 
- 
0.9 (0.7-1.1) 
Ethnic description 
Other  
White 
Not known 
 
- 
1.2 (0.7-2) 
1.1 (0.6-1.9) 
IMD rank 
1 
2 
3 
4 
5 
 
- 
1.1 (0.9-1.3) 
1.2 (0.9-1.6) 
0.9 (0.7-1.2) 
1.3 (1-1.7) 
Place of death 
Hospice 
Hospital 
3DWLHQW¶VKRPH 
Care home 
Other 
 
- 
1.4 (1.1-1.7)* 
2.6 (2.1-3.1)** 
2.8 (2.1-3.9)** 
1.7 (0.9-3.2) 
Cancer site 
Lung 
Upper GI 
Colorectal 
Breast 
Prostate 
Urological  
Gynaecological 
 
- 
1.2 (0.9-1.6) 
1.2 (0.9-1.6) 
1.3 (0.9-2) 
0.5 (0.3-0.8)** 
0.9 (0.6-1.3) 
1 (0.7-1.5) 
21 
 
Variable Predicting late strong opioid prescription 
Head & Neck 
Brain & Neurological 
Primary Unknown 
Other 
1.2 (0.8-1.8) 
4 (1.9-8.5) 
2.1 (0.9-4.4) 
1 (0.7-1.6) 
Survival  
Diagnosis to death (months) 
 
0.9 (0.9-0.9)** 
Oncology treatment 
Surgery 
   No 
   Yes 
Radiotherapy 
   No 
   Yes 
Chemotherapy 
   No 
   Yes 
Hormone therapy 
   No 
   Yes 
 
 
- 
1.4 (1.1-1.7)* 
 
- 
0.7 (0.6-0.9)** 
 
- 
0.7 (0.6-0.8)** 
 
- 
0.9 (0.6-1.5) 
 
 
Figure 1 Proportion of patients receiving at least one prescription event by strong opioid 
category 
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Figure 2 Cumulative proportion of patients prescribed analgesics week by week for the last 
year of life 
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Figure 3 
Proportion of patients (%) who receive an early or late strong opioid prescription by age at 
diagnosis.
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